P. Patel , D. Shan , L. Styskal , L. Chang , D. H. Wilson , M. J. Conrad , P. Jarolim Quanterix Corporation, Lexington, MA, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Resources by Therapeutic Area
Fully automated ultrasensitive digital immunoassay for troponin using single molecule array technology
2015 American Association for Clinical Chemistry
Scientific Reports | May 31, 2016
Implementation of amyloid biomarkers in clinical practice would be accelerated if such biomarkers could be measured in blood. This study analyzes plasma levels of Aβ42 and Aβ40 in a cohort of 719 individuals using a ultrasensitive Simoa platform.
November 18, 2015
American Laboratory Read the article at www.americanlaboratory.com.
Our studies show that there is no age-related PCH in disease free 24-month-old C57BL/6 mice and that restoring GDF11 in old mice has no effect on cardiac structure or function.
Researchers Use Quanterix’s Simoa Technology to Detect Early Indicators of Potential Adverse Cardiovascular Outcomes
LEXINGTON, MA – August 26, 2015 Quanterix Corporation, a leader in high definition diagnostics, today announced that The Journal of Clinical Chemistry has published a new study in which its single molecule array technology (Simoa) was used to measure cardiac troponin I (cTnI) levels with both high a…